{
  "id": 8114955,
  "title": "Theravance Biopharma SVP Rhonda Farnum sells $226k in stock",
  "url": "https://urgent.news/2026/09/17/theravance-biopharma-svp-rhonda-farnum-sells-226k-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-17T22:19:55.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/theravance-biopharma-svp-rhonda-farnum-sells-226k-in-stock-93CH-4906537"
  },
  "original_language": "en",
  "account": "Theravance Biopharma's Senior Vice President of Communications & Medical Affairs, Rhonda Farnum, sold 13,314 shares of the company's stock on September 15, 2026, for a total of $226,793. The sale was made through a pre-arranged 10b5-1 trading plan established on September 3, 2025. As of the sale, Farnum holds 213,476 shares of Theravance Biopharma. The company's stock is currently trading at $17.04, with a market capitalization of approximately $885 million. Analysts consider the stock overvalued, placing it on the Most Overvalued list. Despite recent developments, including a proposed acquisition by Zymeworks Inc., Farnum has remained committed to her role at the biopharmaceutical company.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}